Navigation Links
Cardium Announces Retirement of Director
Date:1/26/2009

l for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate(TM) is initially being developed to be administered once or twice for the potential treatment of non-healing diabetic foot ulcers. Other potential applications for TRC's Gene Activated Matrix(TM) (GAM) technology include therapeutic angiogenesis (cardiovascular ischemia, peripheral arterial disease) and orthopedic products, including hard tissue (bone) and soft tissue (ligament, tendon, cartilage) repair. For more information about Cardium's Tissue Repair Company subsidiary, please visit www.t-r-co.com.

Cardium's Generx product candidate (alferminogene tadenovec, Ad5FGF-4) is a DNA-based growth factor therapeutic being developed for potential use by interventional cardiologists as a one-time treatment to promote and stimulate the growth of collateral circulation in the hearts of patients with ischemic conditions such as recurrent angina. For more information about Cardium Therapeutics and its businesses, products and therapeutic candidates, please visit www.cardiumthx.com or view its 2007 Annual Report at http://www.cardiumthx.com/flash/pdf/CardiumAR07_Book_FINAL.pdf.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. For example, there can be no assurance that results observed in one study or using one type of product or procedure will be replicated in subsequent studies or in studies using new
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cardiums InnerCool Announces First Patient Treated With New Tissue-Specific UroCool(TM) System in Robotic-Assisted Prostate Surgery Study
2. Cardiums InnerCool Announces New Tissue-Specific UroCool(TM) System for Use in Prostate Surgeries
3. Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units
4. Cardium Announces FDA 510(K) Clearance of InnerCools RapidBlue(TM) Endovascular System
5. ITGI Medical Received a CE Mark for its Second Pericardium Covered Stent - AneuGraft(R) - for Tortuous Vessels
6. Cardium Announces InnerCools New RapidBlue(TM) System Obtains CE Mark for Commercial Sale in Europe and UL certification
7. Cardium Announces Follow-On Direct Investment by Institutional Investor
8. Cardium Selected for Inclusion in Russell Microcap Index
9. Cardiums InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems
10. Cardium Launches New AWARE Clinical Study Website
11. Over and Under(R) Pericardium Covered Stent is now in use in England and Proves Great Deliverability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... (PRWEB) October 20, 2014 Convey ... that a team from Iowa State University won first ... contest. Using a Convey HC-2ex, the team’s solution achieved ... times faster than the second place finisher. , Experts ... embarked upon the month long challenge, using a variety ...
(Date:10/20/2014)... BOSTON , Oct. 20, 2014 ... commercialization company tackling big healthcare problems, announced today ... investment round, with participation from Invesco Perpetual, a ... be used to drive PureTech,s existing pipeline forward ... technologies. "PureTech has the scientific creativity to really ...
(Date:10/19/2014)... October 20, 2014 OCTOBER ... Meeting (ABIM). ABIM will take place ... information about ABIM 2014 is now available ... Delegates representing companies and organizations from all ... obtain information on the latest products and ...
(Date:10/19/2014)... 2014 The report "Chocolate, Cocoa Beans, ... Prices, Geography Trend and Forecast (2011 - 2016)," ... geography and studies the major market drivers, restraints, and ... and Asia. , The global chocolate market is expected ... in 2016 at an estimated CAGR of 2.7% from ...
Breaking Biology Technology:Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 2Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 4
... BASEL, Switzerland, Dec. 5 Roche (SWX:,ROG.VX; RO.S) announced ... (Nasdaq: VMSI ), as required by Ventana,s bylaws, ... of directors at,Ventana,s 2008 annual stockholders meeting., On ... acquire all of the,outstanding common shares of Ventana for ...
... Cost, Savings and Avoidance of Approximately $1.5 Billion by 2010 and Incur, Associated ... ... 11% Increase in Indicative Dividend for 2008 and Declares ... Quarterly Dividend, * Revises 2007 Full-Year GAAP EPS Guidance to ...
... January for lead antibody program ... ... Inc. (TSX:,ARI), a biotechnology company discovering and developing the next wave of,antibody ... transfer agreement for its CD44 Cancer,Stem Cell antibody with Avid Bioservices, a ...
Cached Biology Technology:Roche to Nominate Independent Directors for Election at Ventana's 2008 Annual Stockholders Meeting 2Roche to Nominate Independent Directors for Election at Ventana's 2008 Annual Stockholders Meeting 3Roche to Nominate Independent Directors for Election at Ventana's 2008 Annual Stockholders Meeting 4Roche to Nominate Independent Directors for Election at Ventana's 2008 Annual Stockholders Meeting 5Roche to Nominate Independent Directors for Election at Ventana's 2008 Annual Stockholders Meeting 6Roche to Nominate Independent Directors for Election at Ventana's 2008 Annual Stockholders Meeting 7Roche to Nominate Independent Directors for Election at Ventana's 2008 Annual Stockholders Meeting 8Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 2Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 3Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 4Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 5Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 6Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 7Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 8Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 9Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 10Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 11ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody 2ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody 3
(Date:10/16/2014)... constantly wages war on the human body. Battles ... stalemate. In pancreatic cancer, this stalemate—known as tumor ... aggressively malignant, a phenomena that is poorly understood. ... the laboratory of Salvatore Torquato, a Professor of ... conditions surrounding tumor dormancy and the switch to ...
(Date:10/16/2014)... new synthesis of recent research findings to inform their ... two states. , The Ecology and Management of ... Synthesis of the Relevant Biophysical Science and Implications for ... the U.S. Forest Service,s Pacific Northwest Research Station, is ... a synthesis of the large body of scientific information ...
(Date:10/16/2014)... efficiently, they are anything but sustainable: environmental damage ... is becoming increasingly evident. Despite their disadvantages, however, ... regarded as the sole possibility of achieving higher ... Bernhard Schmid, an ecology professor at the University ... agriculture and forestry. After all, a new study ...
Breaking Biology News(10 mins):Modeling tumor dormancy 2New report synthesizes best available science on management of moist mixed-conifer forests 2Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3
... 16, 2013) A team of American and Chinese conservationists ... counted nearly 1,000 wild yaks from a remote area of ... this species, which was decimated by overhunting in the mid ... rugged area called Hoh Xil a national nature reserve ...
... 2013 Elsevier, a world-leading provider of scientific, technical ... announce the launch of a new journal, Journal ... ). JUOGR is to publish ... practices in the area of evaluation, development and management ...
... $14 million from the William & Nancy Thompson Family ... County, UC Irvine is helping lead the charge against ... in the U.S. autism., The funding created the ... which will provide unparalleled access to assessment, diagnosis, care ...
Cached Biology News:Yaks are back 2UCI research turns the corner on autism 2UCI research turns the corner on autism 3
CleanBox DNA workstation with two 254nm UV lambs & 12-hr timer, 90cm (36-inch)width, single door, 115V (w/crating)...
Mouse monoclonal antibody raised against a partial recombinant VRK2. NCBI Entrez Gene ID = VRK2...
Mouse monoclonal antibody raised against a full length recombinant PPIL2. NCBI Entrez Gene ID = PPIL2...
Mouse monoclonal antibody raised against a partial recombinant L3MBTL2. NCBI Entrez Gene ID = L3MBTL2...
Biology Products: